Joint research aimed at developing anticancer drug compounds into treatments for ophthalmic diseases
First written in FY2025. 2 of 3 entries say "Restated". Latest entry: 2026-07-15.
No other company in this theme has enough history to compare yet.
- 2026-07-15RestatedEarnings
「In 2025, we began 2 joint research projects with D.Western Therapeutics Institute, Inc. and 千寿製薬株式会社, respectively, to explore the potential of our compounds as treatments for ophthalmic diseases, and the respective research projects are still ongoing.」
The 2 joint research projects exploring the potential of the compounds as treatments for ophthalmic diseases are continuing. - FY2026-H1RestatedAnnual report
「In 2025, we began 2 joint research projects with D.Western Therapeutics Institute, Inc. and 千寿製薬株式会社, respectively, to explore the potential of our compounds as treatments for ophthalmic diseases, and the respective research projects are still ongoing.」
Joint research in the ophthalmic disease field with The D. Western Therapeutics Institute, Inc. and Senju Pharmaceutical Co., Ltd. is ongoing. - FY2025First statedAnnual report
「In July 2025, the Company began joint research with 株式会社デ・ウエスタン・セラピテクス研究所, and in August 2025 with 千寿製薬株式会社, to explore the potential of different Company compounds as treatments for ophthalmic diseases.」
The company indicated for the first time that it was exploring, through joint research with companies, the potential to develop treatments for non-cancer ophthalmic diseases in order to maximize the value of its oncology pipeline.